← All trials
NCT05328440
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 20, 2022
- Primary completion
- Jun 1, 2024
- Completion date
- Jan 1, 2026
- First posted
- Apr 14, 2022
- Last posted
- Sep 25, 2023
- Enrollment
- 120
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Henan Medical UniversityLead sponsor
- Henan Medical UniversityOfficial
- Henan Medical UniversitySponsor investigator
- Hengrui Therapeutics, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.